This segment focuses on the research, development, and commercialization of innovative drugs for the treatment of various cancers, with a primary focus on non-small cell lung cancer (NSCLC). Key activities include the development of targeted therapies, such as Icotinib hydrochloride and Ensartinib hydrochloride, which are epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors, respectively. Research and development efforts involve clinical trials, drug discovery, and the investigation of new drug candidates. The segment leverages advanced technologies and methodologies in drug development, including molecular biology and medicinal chemistry. The patient impact is significant, as these therapies address unmet medical needs in cancer treatment, improving patient survival rates and quality of life. Betta Pharmaceuticals has positioned itself as a leader in the oncology sector in China, with a focus on providing effective and accessible cancer treatments. Future opportunities include expanding the product pipeline, entering new therapeutic areas, and expanding into global markets. Regulatory and clinical aspects are crucial, with a focus on obtaining approvals from regulatory bodies like the NMPA. Partnerships and collaborations are essential for clinical trials and market access.